The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. - Test2 - elhamkhani - TriplyDB

The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys.

The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys.

http://www.wikidata.org/entity/Q35196195

about

Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Antidiabetes Drugs PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease Adaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous system A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys A synopsis on the role of tyrosine hydroxylase in Parkinson's disease Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.Nonuniform cardiac denervation observed by 11C-meta-hydroxyephedrine PET in 6-OHDA-treated monkeys Influence of drug transporters and stereoselectivity on the brain penetration of pioglitazone as a potential medicine against Alzheimer's disease Oxaliplatin neurotoxicity involves peroxisome alterations. PPARγ agonism as preventive pharmacological approach.Cardiac sympathetic denervation in 6-OHDA-treated nonhuman primates.Systemic administration of 6-OHDA to rhesus monkeys upregulates HLA-DR expression in brain microvasculature Circadian rhythms, Wnt/beta-catenin pathway and PPAR alpha/gamma profiles in diseases with primary or secondary cardiac dysfunction.Nuclear receptors in neurodegenerative diseases.Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates PGC-1α activity in nigral dopamine neurons determines vulnerability to α-synuclein Sustained expression of PGC-1α in the rat nigrostriatal system selectively impairs dopaminergic function.Telmisartan directly ameliorates the neuronal inflammatory response to IL-1β partly through the JNK/c-Jun and NADPH oxidase pathways.Liver X receptor β protects dopaminergic neurons in a mouse model of Parkinson disease Peroxisome proliferator-activated receptors γ/mitochondrial uncoupling protein 2 signaling protects against seizure-induced neuronal cell death in the hippocampus following experimental status epilepticus.Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease.The possible association between Toxoplasma gondii infection and risk of anxiety and cognitive disorders in BALB/c mice.Induced pluripotent stem cell-derived neural cells survive and mature in the nonhuman primate brain.Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR- γ Agonist against MPTP.Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects.PPAR- γ impairment alters peroxisome functionality in primary astrocyte cell cultures.Neuroprotective Effect and Mechanism of Thiazolidinedione on Dopaminergic Neurons In Vivo and In Vitro in Parkinson's Disease.Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease?Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders.PPARγ and PGC-1α as therapeutic targets in Parkinson's.Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease.The ongoing pursuit of neuroprotective therapies in Parkinson disease.Current disease modifying approaches to treat Parkinson's disease.The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease.Microglial phenotypes in Parkinson's disease and animal models of the disease.Real-Time Intraoperative MRI Intracerebral Delivery of Induced Pluripotent Stem Cell-Derived Neurons.Localization of PPAR isotypes in the adult mouse and human brain.Nonhuman Primate Models of Neurodegenerative Disorders.Interactions Between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma on Neuroinflammation, Demyelination, and Remyelination in Multiple Sclerosis.Structural improvement of new thiazolidinones compounds with antinociceptive activity in experimental chemotherapy-induced painful neuropathy.

P2860

Q27301100-43697DBF-570C-4C91-BB88-E8689D930E2B Q27676922-7CA78D7C-F09E-43A5-BFA5-43367366BD86 Q28069549-952F2CF0-F906-4CA3-9465-A0F88DDA77DF Q28389419-8084AF79-EF50-4DE5-B052-BA62E8C75D83 Q28728201-37B17398-B275-4793-86CC-E925417CFFEC Q28830946-45E687AA-7051-4C0B-950A-98D7599750E0 Q30357397-EBF73E36-9615-49B2-99FF-2FB36F1D4975 Q31059759-1946C110-40EC-4A7E-9BF7-6C0A0BD5EBB6 Q33562308-709EA779-D0C7-4687-B778-EFED3E916D6C Q33921641-314F9F9B-14DB-405E-BD5C-E6CC3477D4C9 Q34061568-07F4EA69-4575-4D97-BA03-1CD35AB9C34B Q34237258-27E95650-BB5A-4C4C-8087-0D9DFBA8CF5C Q34452078-278FE949-0E4D-4497-B746-78CA8CE7D921 Q34580020-7B82EC02-ECF5-4AF0-8D25-BC10B87CAE06 Q34626758-15BE6A16-3C0B-4B9F-8384-E4AE7E9D068C Q35233106-F423C5DF-6AE0-46AB-894D-1F52956E9210 Q35856269-016D38A6-1020-4C20-AB89-CCEF85776251 Q36136825-AC23575B-DF80-42CC-9639-A17DD687272D Q36167615-822CED71-D36E-4B46-8591-451DB7823A13 Q36241486-1F5D1936-6DB5-4FD0-B9FD-37B4B286A183 Q36474039-C81C7E69-8716-4458-BF11-F6E35E5864A9 Q36733302-BF9CE93B-3E4E-4B3A-9313-67FB25BF6259 Q36787847-33033467-7FAB-4384-95D3-3173F4FF8375 Q37256315-5F87DC8C-11B1-43D1-9CB7-710134CCB7EC Q37334469-DF20AB5F-BF32-4393-8D17-93257B159374 Q37650379-5F7BBBA5-9C1F-46A3-B070-E3F417DECFE4 Q37710232-67EC1804-4B58-4271-A405-8BEE88CD8EDC Q38032481-8D69C16B-E4BB-422E-B4BC-06AEC1D73693 Q38075505-1DCFD941-30CB-4EDE-AB5F-76C736A8204A Q38227702-1F6E6981-95BC-4BDF-B3B7-200233B5E0C2 Q38250185-AB73E4C6-DD1C-4B20-ABBC-EBB8D536848B Q38275171-FAED1A23-52BB-4232-AC26-A05A0C751B41 Q38652153-8E37F969-5958-43CE-975B-2D8AA0065062 Q38670012-14DA9258-1998-4ADA-A567-265CF6241457 Q38815779-2F0B5B02-0DE2-4440-AAFF-230B25292ED4 Q40579402-DB503C15-F1A8-4340-995A-165E997F5214 Q42735293-0C79AD5E-5B2D-4098-AACD-C430279B4795 Q47687033-4DC1344F-0E78-4604-B678-B12D0BF52316 Q47687993-5AA52867-8D53-4741-A5E1-6CD13891921E Q48323975-F45249F4-8CEE-4CA1-95E8-6387AA0FB94F

P2860

The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys.

http://www.wikidata.org/entity/Q35196195

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

The PPAR-γ agonist pioglitazon ...... ction in parkinsonian monkeys.

@ast

The PPAR-γ agonist pioglitazon ...... ction in parkinsonian monkeys.

@en

type

label

The PPAR-γ agonist pioglitazon ...... ction in parkinsonian monkeys.

@ast

The PPAR-γ agonist pioglitazon ...... ction in parkinsonian monkeys.

@en

prefLabel

The PPAR-γ agonist pioglitazon ...... ction in parkinsonian monkeys.

@ast

The PPAR-γ agonist pioglitazon ...... ction in parkinsonian monkeys.

@en

P1433

Q35196195-D2EE18D1-8C0D-4434-9AA2-47B21FCEBFA9

P1476

Q35196195-BCDD0A71-7DD1-43E1-8809-30876ABBE92D

P2093

Q35196195-0D35CD5D-0C95-41F2-AF03-343E67F9A162

Q35196195-1917C695-414F-427B-AD74-E27EB0C77132

Q35196195-5C32C7AC-FECC-4A2D-8B78-AE4C32DC8B7C

Q35196195-69C68ADC-1B1A-42DF-9BA1-3214500B4D3F

Q35196195-CCD49084-C2FB-440E-9DE7-FE3413DB1E49

Q35196195-CDEDF077-4229-418A-A11E-2DD0430715AA

Q35196195-FC5FAFC4-9A3D-4F43-89ED-13059C0523CF

Q35196195-FFC0EBFF-2445-4EBA-8D8A-0EC7AFDE98E6

P2860

Q35196195-000C9EFA-7936-4547-8FA8-97120D62A3EB

Q35196195-08360AD4-331B-445A-8B02-3EF2E31DFA32

Q35196195-08747834-7385-4F95-8002-071C76EF34A8

Q35196195-09CAB10E-3A8B-4243-AD58-5EF704B58129

Q35196195-0CC35B26-175D-40EC-966F-D1B2E6E49D71

Q35196195-101DEE24-AC6B-4756-AA3D-C23AA2093863

Q35196195-14210756-1D7F-40F1-ADEC-D6D992FD1A22

Q35196195-1DA2942A-98C2-44DA-AFFF-027D4D8FA1B1

Q35196195-20ECF2FF-AF5C-4F26-AE5A-B6925AA6A011

Q35196195-26FC2C6B-C8F4-47DD-A6C5-7151FDEE1A41

P2888

Q35196195-F677A2A8-2E55-42CD-8840-88BB8D9BA9D0

P304

Q35196195-3B3F3FEE-8191-476F-8CEB-8F720F3C4710

P31

Q35196195-D1B09CAE-C002-4900-B1EF-480A80EB1FD0

P356

Q35196195-90E692A8-3666-4DEB-AB6F-C394584C90D5

P478

Q35196195-E5D8435D-C0DB-4C52-B418-94BB5CDAEEB3

P50

Q35196195-EB71FABF-4567-4B6A-97AC-44CCFD8CAB62

P577

Q35196195-90668AA1-CEE1-407A-B3D0-A8EC35BF9854

P5875

Q35196195-18B78311-8FD7-46F9-A3D5-C848169248A8

P6179

Q35196195-E9016D4E-B668-4318-8A13-4E0421478F59

P698

Q35196195-4A99B8A2-DA97-4BF1-A506-29C2A1163401

P921

Q35196195-16C939D3-957B-4D51-8B2E-ED1E52187E9F

P932

Q35196195-456D54B3-BFD6-45A0-BC1F-66BF8225F27C

P356

P1433

Journal of Neuroinflammation

P1476

The PPAR-γ agonist pioglitazon ...... ction in parkinsonian monkeys.

@en

P2093

Christine R Swanson

http://www.w3.org/2001/XMLSchema#string

Heather A Simmons

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Johnson

http://www.w3.org/2001/XMLSchema#string

Joseph W Kemnitz

http://www.w3.org/2001/XMLSchema#string

Kevin Brunner

http://www.w3.org/2001/XMLSchema#string

Toni E Ziegler

http://www.w3.org/2001/XMLSchema#string

Valerie Joers

http://www.w3.org/2001/XMLSchema#string

Viktoriya Bondarenko

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of pioglitazone treatment on behavioral symptoms in autistic children

Neuroinflammation in Parkinson's disease: a target for neuroprotection?

Realistic expectations for treatment success in Alzheimer's disease.

A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease.

The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method

Peroxisome proliferator-activated receptors in inflammation control.

Thiazolidinediones: a comparative review of approved uses.

Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF

Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial.

Nonhuman primate models of Parkinson's disease.

P2888

P304

91

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1742-2094-8-91

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Marina Elena Emborg

P577

2011-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51550072

http://www.w3.org/2001/XMLSchema#string

P6179

1003483182

http://www.w3.org/2001/XMLSchema#string

P698

21819568

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3166925

http://www.w3.org/2001/XMLSchema#string